Answers are grounded in this paper and cite their sources.
The design and application of radioactively labeled drugs for cancer treatment are experiencing a rebirth, led in part by new advances in radioligand therapies (RLTs) like 177 Lu-PSMA-617 and 177 Lu-DOTATATE that specifically and potently bind to proteins highly upregulated in cancer. This review discusses the latest advances in RLT design that aim to maximize radiation delivery to tumor tissue while sparing normal tissues from greater than minimal radioactive dose.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: